Lexaria Bioscience (LEXX) Capital Expenditures (QoQ) (2011 - 2025)
Lexaria Bioscience (LEXX) Capital Expenditures (QoQ) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2025 | 200.00% |
| May 31, 2025 | -200.00% |
| Feb 28, 2025 | -100.00% |
| Nov 30, 2024 | -42.70% |
| Feb 28, 2023 | -35.38% |
| Nov 30, 2022 | 512,400.00% |
| Aug 31, 2022 | -99.94% |
| Aug 31, 2019 | -95.13% |
| May 31, 2019 | -38.58% |
| Feb 28, 2019 | 159.15% |
| May 31, 2016 | 200.00% |
| Feb 29, 2016 | -109.99% |
| Jan 31, 2014 | -8.20% |
| Oct 31, 2013 | 27,132.00% |
| Jul 31, 2013 | -99.63% |
| Apr 30, 2013 | -26.93% |
| Jan 31, 2013 | 37.36% |
| Oct 31, 2012 | -86.61% |
| Jan 31, 2012 | -93.73% |
| Apr 30, 2011 | -83.76% |